Agios Pharmaceuticals Inc (AGIO)
55.48
-3.10
(-5.29%)
USD |
NASDAQ |
Nov 14, 16:00
53.22
-2.26
(-4.07%)
After-Hours: 20:00
Agios Pharmaceuticals Research and Development Expense (Quarterly): 72.46M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 72.46M |
| June 30, 2024 | 77.40M |
| March 31, 2024 | 68.62M |
| December 31, 2023 | 77.49M |
| September 30, 2023 | 81.84M |
| June 30, 2023 | 68.90M |
| March 31, 2023 | 67.30M |
| December 31, 2022 | 70.30M |
| September 30, 2022 | 64.97M |
| June 30, 2022 | 74.52M |
| March 31, 2022 | 70.12M |
| December 31, 2021 | 73.30M |
| September 30, 2021 | 64.00M |
| June 30, 2021 | 62.01M |
| March 31, 2021 | 57.67M |
| December 31, 2020 | 59.42M |
| September 30, 2020 | 51.94M |
| June 30, 2020 | 54.09M |
| March 31, 2020 | 55.36M |
| December 31, 2019 | -90.38M |
| September 30, 2019 | 101.67M |
| June 30, 2019 | 107.39M |
| March 31, 2019 | 95.58M |
| December 31, 2018 | 93.81M |
| September 30, 2018 | 82.56M |
| Date | Value |
|---|---|
| June 30, 2018 | 86.73M |
| March 31, 2018 | 78.22M |
| December 31, 2017 | 77.22M |
| September 30, 2017 | 72.92M |
| June 30, 2017 | 79.82M |
| March 31, 2017 | 62.73M |
| December 31, 2016 | 64.68M |
| September 30, 2016 | 60.64M |
| June 30, 2016 | 50.80M |
| March 31, 2016 | 44.04M |
| December 31, 2015 | 36.93M |
| September 30, 2015 | 36.03M |
| June 30, 2015 | 36.42M |
| March 31, 2015 | 32.44M |
| December 31, 2014 | 34.86M |
| September 30, 2014 | 25.53M |
| June 30, 2014 | 22.58M |
| March 31, 2014 | 17.41M |
| December 31, 2013 | 15.28M |
| September 30, 2013 | 14.80M |
| June 30, 2013 | 12.96M |
| March 31, 2013 | 11.46M |
| December 31, 2012 | 11.22M |
| September 30, 2012 | 9.798M |
| June 30, 2012 | 10.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-90.38M
Minimum
Dec 2019
81.84M
Maximum
Sep 2023
59.07M
Average
67.96M
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.598B |
| Regeneron Pharmaceuticals Inc | 1.272B |
| Ligand Pharmaceuticals Inc | 5.675M |
| ADMA Biologics Inc | 0.412M |
| AnaptysBio Inc | 42.21M |